A representative of AstraZeneca in Brazil announced today, Monday, the resumption of clinical trials of its anti-Coronavirus vaccine, which the company is developing in cooperation with the University of Oxford, after the country’s Health Regulatory Authority obtained confirmation that its British counterpart had resumed trials.
The Federal University of Sao Paulo, which is conducting the experiments, said in a statement that it had given the vaccine to 4,600 out of 5,000 volunteers in Brazil, without any of them reporting any serious health problems.
The experiments involved volunteers from Sao Paulo, Rio de Janeiro and Salvador in the northeastern state of Bahia.
AstraZeneca suspended global
testing last week after an unexplained illness of a participant in Britain.
Brazil is suffering from the third worst outbreak of the Corona virus after the United States and India, and it has become an attractive ground for testing anti-Covid-19 vaccines developed by Britain, China and Russia.